ORIGINAL COMMUNICATION

Motor and non-motor outcome in tremor dominant Parkinson's disease after MR-guided focused ultrasound thalamotomy

Veronika Purrer[1,2] · Emily Pohl[1] · Valeri Borger[3] · Hannah Weiland[4] · Henning Boecker[2,4] · Frederic Carsten Schmeel[2,5] · Ullrich Wüllner[1,2]

Abstract

Background and objectives Magnetic Resonance-guided Focused Ultrasound (MRgFUS) is an emerging technique for the treatment of severe, medication-refractory tremor syndromes. We here report motor and non-motor outcomes 6 and 12 months after unilateral MRgFUS thalamotomy in tremor-dominant Parkinson's disease (tdPD).

Methods 25 patients with tdPD underwent neuropsychological evaluation including standardized questionnaires of disability, quality of life (QoL), mood, anxiety, apathy, sleep disturbances, and cognition at baseline, 6 and 12 months after MRgFUS. Motor outcome was evaluated using the Clinical Rating Scale for Tremor (CRST) and Movement Disorder Society–Unified Parkinson's Disease Rating Scale (MDS-UPDRS). In addition, side effects and QoL of family caregivers were assessed.

Results 12 months after MRgFUS significant improvements were evident in the tremor subscores. Patients with concomitant rest and postural tremor showed better tremor outcomes compared to patients with predominant rest tremor. There were no differences in the non-motor assessments. No cognitive decline was observed. Side effects were mostly transient (54%) and classified as mild (62%). No changes in the caregivers' QoL could be observed.

Conclusion We found no changes in mood, anxiety, apathy, sleep, cognition or persistent worsening of gait disturbances after unilateral MRgFUS thalamotomy in tdPD. Concomitant postural tremors responded better to treatment than predominant rest tremors.

Keywords Non-motor symptoms · Tremor · Thalamotomy · Focused ultrasound · Parkinson's disease

Abbreviations

AC	Anterior commissure
ADL	Activities of daily living
AES	Apathy evaluation scale
BDI	Beck Depression Inventory
C-GIC	Clinical Global Impression of Change-Scale
CRST	Clinical Rating Scale for Tremor
CRSTmod	Modified, hand-specific subscore of the CRST
CST	Corticospinal tract
CTT	Cerebello-thalamic tract
DBS	Deep brain stimulation
DTI	Diffusion tensor imaging
ESS	Epworth Sleepiness Scale
FAQ	Functional Activities Questionnaire
GDS	Geriatric Depression Scale
LED	Levodopa equivalent doses
MCS	Mental Component Scale
MDS-UPDRS	Movement Disorder Society–Unified Parkinson's Disease Rating Scale
ML	Lemniscus medialis
MoCA	Montreal Assessment of Cognition
MRgFUS	Magnetic Resonance-guided Focused Ultrasound
NMSQuest	Non-motor Symptoms Questionnaire
PC	Posterior commissure

✉ Veronika Purrer
Veronika.Purrer@ukbonn.de

1 Department of Neurology, University Hospital Bonn, Venusberg-Campus 1, 53127 Bonn, Germany

2 German Centre of Neurodegenerative Diseases (DZNE), Bonn, Bonn, Germany

3 Department of Neurosurgery, University Hospital Bonn, Bonn, Germany

4 Department of Diagnostic and Interventional Radiology, University Hospital Bonn, Bonn, Germany

5 Department of Neuroradiology, University Hospital Bonn, Bonn, Germany

PCS	Physical Component Scale
PD	Parkinson's Disease
PDQ-39	39-Item Parkinson's Disease Questionnaire
P-GIC	Patient Global Impression of Change-Scale
PQoL Carers	Parkinsonism Carers QoL Questionnaire
QoL	Quality of life
RBDSQ	REM Sleep Behavior Disorder Screening Questionnaire
SARA	Scale for the assessment and rating of ataxia
SF-36	Short-Form-36 questionnaire
STAI-T	State-Trait Anxiety Scale—"trait" anxiety
T0	Evaluation 1–2 days prior to MRgFUS
T1	Evaluation 1–3 days after MRgFUS
T2	Evaluation 6 months after MRgFUS
T3	Evaluation 12 months after MRgFUS
Td	Tremor dominant
VIM	Ventral intermediate nucleus
VLa	Anterior part of the ventrololateral nucleus
VLpd	Posterodorsal part of the ventrolateral nucleus
VLpv	Posteroventral part of the ventrolateral nucleus
Voa	Ventri-oralis anterior nucleus
Vop	Ventri-oralis posterior nucleus

Introduction

Parkinson's disease (PD) is characterized clinically by a variety of motor and non-motor symptoms. PD is increasingly considered a heterogeneous syndrome rather than a clear-cut entity, which is evident also with regard to the main clinical subtypes, i.e. tremor dominant (tdPD), akinetic-rigid or postural instability and gait difficulty type [1]. The prevalent tremor in PD is an asymmetric resting tremor suppressed upon movement initiation. This rest tremor is often accompanied by kinetic and/or postural tremor and the underlying tremor generator(s) remain ill-defined [2]. TdPD patients may experience slower disease progression [1], but the tremor as such can be disabling [3] and medical treatment is often ineffective [4]. Thus, stereotactic treatments, in particular deep brain stimulation (DBS) and thalamotomy, have been successfully used in medication-refractory tremors for many years [5]. Herein, common targets include the posteroventral part of the ventrolateral nucleus of the thalamus (VLpv; corresponding to the ventral intermediate nucleus (VIM) in the Schaltenbrand atlas [6]).

The Magnetic Resonance-guided Focused Ultrasound (MRgFUS), which enables interventional neuromodulation by selective thermal lesions of defined structures in the central nervous system without opening the skull has re-awakened the interest in lesional approaches and several studies demonstrated the efficacy and safety of the procedure in tdPD [7–9]. While motor efficacy and side effects such as paraesthesias are observed immediately or within the first few days after treatment, waning effects or effects on cognition and other neuropsychological symptoms might occur subsequently. Previous studies mainly focused on disability, quality of life and cognition, and neuropsychological changes have been less studied extensively [7, 8, 10, 11].

Herein, we analyzed the clinical outcome of 25 tdPD patients treated with MRgFUS after 6 and 12 months with a special emphasis on safety, neuropsychological measurements and quality of life (QoL) in patients and family caregivers. Furthermore, differences in tremor outcomes in patients with different tremor manifestations were evaluated.

Methods

Patients

From December 2019 to October 2022, we enrolled 25 patients with tdPD according to the IPMDS consensus criteria [2]. The pre-existing diagnosis was confirmed in our outpatient department by two movement disorder neurologists (UW and VP). All patients showed a tremor-dominant subtype classified based on established methods using the Movement Disorder Society–Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III [12] (see Suppl. Methods S1 and [13]). A tremor-dominant subtype was defined by a tremor/non-tremor ratio equal or greater than 1.15. Tremor had to be moderate to severe (score of ≥ 2 in the dominant hand on the Clinical Rating Scale for Tremor (CRST)[14]) and to affect daily activities and/or QoL (score > 2 in the disability suspicion of the CRST or $\geq 30\%$ self-rated reduction of QoL caused by the tremor). Reports of at least two previous medication trials (dopaminergic, anticholinergics, amantadine, clozapine, propranolol, budipine) that failed to achieve satisfactory tremor control were required. Current dopaminergic and other tremor-reducing drugs had to be stable for at least 30 days at the timepoint of enrollment and had to be discontinued prior to treatment (at least 12 h overnight). Exclusion criteria involved structural brain damage, epilepsy, coagulopathies, severe cardiac conditions, history of psychiatric disorders or substance abuse, reported cognitive impairment, or a skull density ratio < 0.3. All patients were also evaluated for and informed about DBS. The study was performed according to the Declaration of Helsinki and

approved by the local Ethics Committee (314/18). All participants provided written informed consent.

25 patients were included in the primary outcome analysis at 6 months. 6 patients were lost to follow-up at 12 months (2 patients with an initial good tremor effect denied the follow-up because of waning effects, unfortunately, further information on the extent of worsening have not become available, 1 patient with stable tremor effect refused follow-up because of health problems, 3 patients because of travelling restrictions caused by the COVID-19 pandemic).

Magnetic resonance-guided focused ultrasound thalamotomy

Treatment was performed in a 3-Tesla MRI system (Discovery MR750w, GE Healthcare, Chicago, IL, USA) and the focused ultrasound system (ExAblate 4000 System, InSightec, Haifa, Israel). The VLpv of the thalamus contralateral to the more affected hand was selected as the target. Localization of the VLpv followed standard stereotactic coordinates (on the level of anterior commissure to posterior commissure (AC-PC) line, 14 mm lateral to midline or 11 mm lateral to the third ventricle wall, 25% of the AC-PC line anterior to PC). Adjustment of the target was based on intraoperative clinical evaluation, i.e. the patient's feedback regarding tremor reduction and possible side effects and the diffusion tensor imaging (DTI)—derived coordinates of the cerebello-thalamic tract (CTT) and selected 'no-go areas', the corticospinal tract (CST) and lemniscus medialis (ML), which had been calculated in advance (details in[15]). For further treatment details, we refer to previous descriptions [16, 17].

Outcomes

Clinical evaluations were conducted by two neurologists (U.W., 28 and V.P., 5 years of experience in movement disorders) directly before the treatment (T0) and 1–3 days after treatment (T1). Follow-up visits were conducted 6 (T2), and 12 months (T3) after MRgFUS.

Efficacy

For assessment of the motor outcome, the CRST and MDS-UPDRS III. were used. Higher values indicated more severe symptoms. The CRST consists of three parts: tremor severity in different body parts (part A), motor task performance for both hands (part B), and subjective functional disability related to the tremor (part C). Tremor outcome was measured using a hand-specific subscore combining parts A and B of the treated upper extremity (CRST$_{mod}$, ranging from 0 to 28) and calculated using the Weber-Fechner equation[18], which accounts for the logarithmic relationship

between tremor rating R and tremor amplitude $T = ((T_f — T_i)/T_i = 10^{(\alpha/N)*\Delta R} — 1)$. Hereby, T is a function of the change in tremor ratings ΔR, α is a coefficient for the 0–4 scale and equals to 0.5, and N is the number of items included in the scale.

According to the clinical rating of rest and postural tremor of the upper extremity on the CRST part A, patients were divided into the predominant rest tremor group (rest/postural ratio ≥ 1.5; $n = 11$) and the concomitant rest and postural tremor group (rest/postural ratio < 1.5; $n = 14$).

To further analyze the target-effect relationship, we divided patients according to their individual outcome into the higher tremor improvement group with $T \geq 0.7$ ($n = 12$) and the lower tremor improvement group with $T < 0.7$ $n = 13$) according to the CRST$_{mod}$ score after 6 months (T2).

MDS-UPDRS subscales for tremor, rigidity, bradykinesia, and axial symptoms were calculated in total and separately for the treated and untreated side. Details on the subscale calculation are provided in the Supplementary Material. Clinical evaluation was conducted in an off-medication state (minimum of 4-h withdrawal of antiparkinsonian drugs).

To determine changes in tremor-reducing drugs, levodopa equivalent doses (LED) (in milligrams per day) were assessed according to established conversion rates; anticholinergics and propranolol were recorded in addition [19].

Non-motor outcomes

We assessed changes in disability (CRST part C, MDS-UPDRS I and II, Non-motor Symptoms Questionnaire (NMSQuest)[20]), QoL (Short-Form-36 questionnaire (SF-36)[21], 39-item Parkinson's Disease Questionnaire (PDQ-39)[22]), mood (Beck Depression Inventory (BDI)[23] and Geriatric Depression Scale (GDS)[24]), "trait" anxiety (State-Trait Anxiety Scale (STAI-T)[25], apathy (Apathy evaluation scale (AES)[26]), sleep disturbances (Epworth Sleepiness Scale (ESS)[27] and REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ)[28]) at baseline, 6 and 12 months and cognition (Montreal Assessment of Cognition (MoCA), at baseline and 12 months.

Relatives were interviewed on the patient's cognition using the Functional Activities Questionnaire (FAQ)[29]. In addition, caregivers' QoL were assessed using the Parkinsonism Carers QoL Questionnaire (PQoL Carers)[30].

Safety

As safety parameters, the incidence and severity of the reported and observed side effects were monitored. Side effects that were only subjective and not clearly related to MRgFUS treatment without impact on daily activities and QoL were classified as mild. Side effects associated with

mild or major restrictions in everyday life were recorded as moderate or severe, respectively. A worsening of motor complications was assessed with the MDS-UPDRS IV. As unsteadiness or gait disturbances are common side effects after MRgFUS treatment, we used the scale for the assessment and rating of ataxia (SARA)[31] and extracted the subitems measuring gait (item 1) and stance (item 2) separately.

Statistical analysis

Data analysis was performed using IBM SPSS Statistics for Windows, version 25 (IBM Corp., Armonk, N.Y., USA). Evaluation of the normal distribution of the data was performed using the Shapiro–Wilk test. Since most of the data were not normally distributed, non-parametric tests were used for further analysis. Friedman's test was used to assess within-group changes of the test variables among all time-points. Post hoc analysis with Wilcoxon signed-rank tests with Bonferroni corrections were used for pairwise comparisons. Differences in tremor outcome between patients with concomitant rest and postural tremor or predominant rest tremor subtype and subgroup analysis of side effects were assessed using the Mann–Whitney U test. The same test was used to evaluate whether changes on the neuropsychological assessments differ between patients with high and low tremor improvement. The changes in the different scales were calculated by subtracting the baseline value from the value at T3.

Correlations between demographic data and the baseline motor and non-motor test scores were assessed using Spearman's correlation coefficient r.

P-values < 0.05 was considered statistically significant.

Results

Patients' demographics

Detailed demographic and clinical characteristics of the 25 patients are given in Table 1.

The mean age was 63.7 ± 11.3 years (range 35 to 82) and the mean disease duration 5.4 ± 2.6 years (range 1 to 10). 23 (92%) patients were right-handed and in 17 (68%) patients the targeted VLpv was located in the left hemisphere. The mean tremor/non-tremor ratio was 2.0 ± 2.0 (range 1.0 to 10.7). Comparing the more to the less severely affected side on the MDS-UPDRS scale, asymmetric tremor (ratio ≥ 1.5) was found in 22 (88%) patients. 1 patient with the initial diagnosis of essential tremor developed (additional) PD after years.

Table 1 Demographic and clinical characteristics of the study participants ($n = 25$)

Characteristic	Value
Age—yr*	63.7 ± 11.3
Male sex—no. (%)	21 (84)
Right-handedness—no. (%)	23 (92)
Age of onset*	58.3 ± 11.7
Disease duration—yr*	5.4 ± 2.6
Dominant hand treated—no. (%)	17 (68)
LED—mg*	567.1 ± 708.4
No. of previous medications received*,#	3.9 ± 1.9
Hoehn and Yahr Scale at baseline – no. (%)	
Stage 1	2 (8)
tage 2	13 (52)
Stage 3	9 (36)
Stage 4	1 (4)

*Values are means ± SD

#Among these: dopaminergic (100%), anticholinergics (40%), amantadine (52%), clozapine (12%), propranolol (40%), budipine (4%)

LED = Levodopa equivalent doses

MRgFUS thalamotomy

The mean SDR was 0.44 ± 0.09 (range 0.30–0.68) and the median skull surface area was 359.8 ± 25.6 cm^2 (range 303–411). On average, 8.7 ± 2.9 (range 5–15) sonications and 3.4 ± 1.5 (range 1–6) ablative sonications (peak voxel temperature > 54 °C) were administered. The mean acoustic energy was 8251.8 ± 3154.7 J (range 3050.9–14,179.8) and the mean peak voxel temperature was 58.8 ± 1.8 °C (range 56.3–61.4). On T1-weighted MRI after 6 months, the median lesion volume was 28.6 ± 19.5 mm^3 (range 10–88).

Tremor improvement

Table 2 summarizes the motor outcomes after MRgFUS. At all follow-up timepoints, a significant reduction in tremor scores and subscores of the treated side was found, with the most marked reduction at T1. Tremor was found to be reduced by 78% at T1, 59% at T2, and 60% at T3. At T1, a significant reduction in rigidity and bradykinesia of the treated side was also observed but was no longer significant at T2 and T3. There were no significant changes in the subscores of the untreated side and the subscore of the MDS-UPDRS III.

Significant correlations were found for age and the MDS-UPDRS III score as well as its subscores for tremor and axial symptoms. Age at onset furthermore correlated with the axial subscore and disease duration with the MDS-UPDRS III total score (Suppl. Table S1.).

Table 2 Motor outcome after MRgFUS

	T0 (n = 25)	Friedman test value*	T1 (n = 25)[#]	T2 (n = 25)[#]	T3 (n = 19)[#]
	Timepoint				
CRST Total score	31.5 ± 15.5	$\chi^2(3) = 32.82$ $p < 0.001$	11.7 ± 8.8 (Z = 2.24, p < 0.001)	19.6 ± 10.4 (Z = 0.97, p = 0.121)	15.4 ± 7.2 (Z = 1.74, < 0.001)
Treated arm (CRST$_{mod}$)[‡]	13.8 ± 5.9	$\chi^2(3) = 39.34$ $p < 0.001$	2.6 ± 2.0 (Z = 2.47, p < 0.001)	5.8 ± 4.0 (Z = 1.58, p = 0.001)	5.1 ± 2.7 (Z = 1.63, p = 0.001)
Untreated arm (CRST$_{mod}$)[‡]	6.0 ± 4.9	$\chi^2(3) = 0.92$ $p = 0.820$	5.8 ± 5.1	6.2 ± 3.8	6.1 ± 5.1
MDS-UPDRS III Total score	35.6 ± 13.4	$\chi^2(3) = 26.28$ $p < 0.001$	22.6 ± 16.5 (Z = 2.11, p < 0.001)	26.2 ± 13.1 (Z = 1.21, p = 0.023)	27.4 ± 18.3 (Z = 1.11, p = 0.050)
MDS-UPDRS III Tremor Total score	10.6 ± 3.1	$\chi^2(3) = 36.05$ $p < 0.001$	3.4 ± 3.1 (Z = 2.40, p < 0.001)	6.1 ± 3.4 (Z = 1.37, p = 0.007)	5.2 ± 2.5 (Z = 1.61, p = 0.001)
Treated side	8.1 ± 1.5	$\chi^2(3) = 35.35$ $p < 0.001$	1.1 ± 1.4 (Z = 2.32, p < 0.001)	3.4 ± 3.0 (Z = 1.42, p = 0.004)	2.6 ± 2.3 (Z = 1.63, p = 0.001)
Untreated side	2.6 ± 2.3	$\chi^2(3) = 1.99$ $p = 0.574$	2.4 ± 2.7	2.7 ± 2.3	2.5 ± 2.5
MDS-UPDRS III Bradykinesia Total score	10.8 ± 6.0	$\chi^2(3) = 8.21$ $p = 0.042$	7.8 ± 7.0 (Z = 1.11, p = 0.050)	8.4 ± 4.9 (Z = 0.63, p = 0.790)	10.1 ± 8.4 (Z = 0.26, p = 1.000)
Treated side	7.1 ± 3.3	$\chi^2(3) = 18.87$ $p < 0.001$	3.7 ± 3.1 (Z = 1.68, p < 0.001)	4.5 ± 2.8 (Z = 1.34, p = 0.008)	5.3 ± 3.5 (Z = 0.97, p = 0.121)
Untreated side	3.7 ± 3.6	$\chi^2(3) = 0.62$ $p = 0.892$	4.1 ± 4.7	3.9 ± 3.6	4.8 ± 5.3
MDS-UPDRS III Rigidity Total score	3.7 ± 2.1	$\chi^2(3) = 17.91$ $p < 0.001$	1.8 ± 1.3 (Z = 1.63, p = 0.001)	2.6 ± 1.9 (Z = 0.82, p = 0.309)	2.8 ± 2.3 (Z = 1.03, p = 0.086)
Treated side	2.4 ± 1.3	$\chi^2(3) = 31.14$ $p < 0.001$	0.6 ± 0.6 (Z = 1.97, p < 0.001)	1.4 ± 0.9 (Z = 0.90, p = 0.196)	1.4 ± 1.2 (Z = 1.24, p = 0.019)
Untreated side	1.3 ± 1.1	$\chi^2(3) = 1.85$ $p = 0.605$	1.2 ± 1.0	1.3 ± 1.2	1.5 ± 1.3
MDS-UPDRS III Axial Total score	6.7 ± 3.9	$\chi^2(3) = 5.32$ $p = 0.150$	8.1 ± 6.1	6.2 ± 5.0	6.8 ± 5.8

Values are means ± SD

*P values are based on the Friedman Test ($p < 0.05$). Patients with completed 12-months follow-up were included ($n = 19$)

[#]Post hoc analysis was conducted for all follow-up time points compared to baseline using the Wilcoxon signed-rank test and Bonferroni correction for multiple comparisons (p' value < 0 0.017)

[‡]The modified score was derived from the CRST, part A (3 items) and part B (4 items) for the treated and untreated upper extremity (range 0–28)

MRgFUS Magnetic Resonance-guided Focused Ultrasound, *T0* Baseline, *T1* 1–3 days post-MRgFUS, *T2* 6 months post-MRgFUS, *T3* 12 months post-MRgFUS, *CRST* Clinical Rating Scale for Tremor, *CRST$_{mod}$* modified score of the Clinical Rating Scale for Tremor, *MDS-UPDRS* Movement Disorder Society–Unified Parkinson's Disease Rating Scale

Comparing patients with concomitant rest and postural tremor (T1: 87%, T2: 72%, T3: 84%) or predominant rest tremor (T1: 67%, T2: 41%, T3: 38%), patients with concomitant rest and postural tremor showed better tremor outcomes at all follow-up timepoints (T1: p < 0.001, T2: $p = 0.003$, T3: $p < 0.001$). Baseline tremor scores were higher in patients with concomitant rest and postural tremor. Nevertheless, significant tremor improvement 12 months after MRgFUS could be found in patients with concomitant rest and postural tremor only (Fig. 1, Suppl. Table S2).

Medication

Medical adjustments were made based on parkinsonian symptoms. 12 months after MRgFUS thalamotomy reductions in medications were observed in 6 (32%) patients while an increase was observed in 11 (58%) patients. A significant increase of LED was observed between timepoint T1 and T3 (Z = -1.37, p = 0.007).

Fig. 1 Tremor improvement after MRI-guided focused ultrasound (MRgFUS) thalamotomy in patients with concomitant rest and postural and predominant rest tremor subtype. 12 months post-MRgFUS, significant tremor improvement was observed in the treated extremity—as shown by modified, hand-specific subscores of the Clinical Rating Scale of Tremor (CRST)—in patients with concomitant rest and postural tremor only

Non-motor outcomes

The non-motor outcomes are given in Table 3. Taken together, only at T1, a significant improvement in the patient's disability, measured by part C of the CRST, was found which no longer reached significance at the other follow-up visits. No changes were observed in the MDS-UPDRS I and II, and NMSQuest. Furthermore, no differences were observed in the neuropsychological assessments measuring general and PD-specific QoL, mood, anxiety, apathy, and sleep disturbances. Cognitive testing (MoCA) and relatives' interview (FAQ) revealed no cognitive decline at 12 months. The MoCA even showed higher values, corresponding to better cognitive performance.

In addition to the patient's outcome, no changes in the caregivers' QoL (PQoL Carers) could be observed (Table 3).

The CRST score prior to treatment (T0) correlated significantly with scales measuring disability (CRST, part C, MDS-UPDRS II, NMSQuest, subscore "daily activity" of the PDQ-39), mood (BDI) and sleep disturbances (ESS, RBDSQ). General (SF-36) and PD-specific QoL (total PDQ-39) did not correlate with the CRST. Moreover, higher age correlated significantly with lower scores in the physical component scale of the SF-36 and the subscore "social support" of the PDQ-39. Age of onset had an impact on the subscore "social support" of the PDQ-39. Duration of tremor did not reveal any significant impact on the different test scores or subdomains at baseline (Suppl. Table S3).

Table 3 Non-motor outcome after MRgFUS

	T0 (n = 25)	Friedman test value*	T1 (n = 25)#	T2 (n = 25)#	T3 (n = 19)#
			Timepoint		
CRST, part C ("disability")	8.3 ± 5.6	$\chi^2(3) = 26.26$ $p < 0.001$	1.8 ± 2.0 (Z = 2.00, $p < 0.001$)	5.2 ± 4.8 (Z = 0.66, $p = 0.698$)	3.3 ± 3.0 (Z = 1.24, $p = 0.019$)
MDS-UPDRS I ("behaviour and mood")	9.5 ± 6.8	$\chi^2(2) = 8.46$ $p = 0.015$		7.4 ± 5.2 (Z = 0.55, $p = 0.266$)	7.2 ± 5.7 (Z = 0.87, p = 0.022)
MDS-UPDRS II ("ADL")	12.3 ± 6.9	$\chi^2(2) = 0.89$ $p = 0.642$		12.6 ± 8.2	12.7 ± 8.9
NMSQuest	6.7 ± 4.3	$\chi^2(2) = 0.40$ $p = 0.819$		6.8 ± 4.1	6.6 ± 3.5
SF-36 PCS	42.2 ± 9.9	$\chi^2(2) = 3.44$ $p = 0.179$		40.3 ± 10.9	43.3 ± 11.5
MCS	45.5 ± 12.5	$\chi^2(2) = 2.33$ $p = 0.311$		48.7 ± 9.0	44.6 ± 15.3
PDQ-39 Summary index	20.1 ± 13.0	$\chi^2(2) = 4.03$ $p = 0.133$		17.6 ± 14.6	20.0 ± 18.2
Mobility	14.7 ± 11.6	$\chi^2(2) = 4.51$ $p = 0.105$		16.7 ± 16.3	20.7 ± 22.2
Daily activity	33.8 ± 19.5	$\chi^2(2) = 5.25$ $p = 0.073$		24.5 ± 20.1	26.8 ± 24.7
Emotional wellbeing	20.7 ± 21.7	$\chi^2(2) = 0.67$ $p = 0.717$		20.0 ± 19.6	21.7 ± 24.1
Stigma	24.3 ± 18.4	$\chi^2(2) = 2.94$ $p = 0.230$		19.0 ± 15.6	17.4 ± 23.0
Social support	9.7 ± 17.0	$\chi^2(2) = 0.84$ $p = 0.657$		8.3 ± 14.0	6.6 ± 11.3
Cognition	23.3 ± 21.7	$\chi^2(2) = 0.68$ $p = 0.713$		18.5 ± 17.4	26.6 ± 23.8
Communication	11.7 ± 14.0	$\chi^2(2) = 1.87$ $p = 0.393$		14.7 ± 20.2	17.1 ± 24.4
Physical Discomfort	22.7 ± 18.9	$\chi^2(2) = 3.58$ $p = 0.167$		19.3 ± 20.1	22.8 ± 24.8
BDI	7.8 ± 5.8	$\chi^2(2) = 2.32$ $p = 0.313$		6.1 ± 4.7	5.9 ± 4.8
GDS	2.3 ± 2.0	$\chi^2(2) = 1.89$ $p = 0.390$		3.0 ± 2.8	1.7 ± 2.2
STAI-T	40.2 ± 10.3	$\chi^2(2) = 6.21$ $p = 0.045$		37.3 ± 8.2 (Z = 0.76, $p = 0.056$)	39.3 ± 13.0 (Z = 0.42, $p = 0.583$)
AES	58.7 ± 7.5	$\chi^2(2) = 0.61$ $p = 0.738$		59.0 ± 7.6	57.3 ± 9.6
ESS	6.5 ± 4.3	$\chi^2(2) = 2.55$ $p = 0.219$		6.9 ± 4.3	5.7 ± 3.2
RBDSQ	3.5 ± 2.1	$\chi^2(2) = 3.03$ $p = 0.280$		2.9 ± 1.9	3.9 ± 2.6
MoCA‡	25.7 ± 3.1				26.3 ± 2.6 (Z = -2.25, $p = 0.024$)
FAQ	1.4 ± 2.1	$\chi^2(2) = 2.00$ $p = 0.368$		2.1 ± 3.0	2.7 ± 4.2
PQoL Carers⁑	18.4 ± 16.3	$\chi^2(2) = 0.63$ $p = 0.729$		22.4 ± 21.0	23.1 ± 25.6

Values are means ± SD

*P values are based on the Friedman Test ($p < 0.05$). Patients with completed 12-months follow-up were included (n = 19)

#Post hoc analysis was conducted for all follow-up time points compared to baseline using the Wilcoxon signed-rank test and Bonferroni correction for multiple comparisons (p' value < 0 0.017)

‡The Wilcoxon signed-rank test was used to compare the baseline and post-12-months score ($p < 0.05$)

⁑n = 17 were included

Table 3 (continued)

MRgFUS Magnetic Resonance-guided Focused Ultrasound, *T0* Baseline, *T1* 1–3 days post-MRgFUS, *T2* 6 months post-MRgFUS, *T3* 12 months post-MRgFUS, *CRST* Clinical Rating Scale for Tremor, *MDS-UPDRS* Movement Disorder Society–Unified Parkinson's Disease Rating Scale, *ADL* Activities of daily living, *NMSQuest* non-motor Symptoms Questionnaire, *SF-36* Short-Form-36 questionnaire, *PCS* Physical Component Scale, *MCS* Mental Component Scale, *PDQ-39* 39-item Parkinson's Disease Questionnaire, *BDI* Beck Depression Questionnaire, *GDS* Geriatric Depression Scale, *STAIT* State-Trait Anxiety Scale—"trait" anxiety, *AES* Apathy evaluation scale, *ESS* Epworth Sleepiness Scale, *RBDSQ* REM Sleep Behavious Disorder Questionnaire, *MoCA* Montreal Assessment of Cognition, *FAQ* Functional Activities Questionnaire, *PQoL Carers* Parkinsonism Carers Quality of Life Questionnaire

Except for the MoCA and FAQ, the neuropsychological scales measuring the same attribute, correlated with each other. The PD-specific QoL (PDQ-39 Summary index) correlated significantly with all disability scales (CRST, part C, MDS-UPDRS I and II, NMSQuest) as well as with depression (BDI, GDS), anxiety (STAIT), apathy (AES), sleep disturbances (ESS, RBDSQ) and cognition (FAQ). The physical component scale (PCS) of the SF-36 correlated negatively with the disability scales MDS-UPDRS I and II and NMSQuest, depressive symptoms (BDI, GDS),

Table 4 Side effects after MRgFUS

	Timepoint			
	Total	T1 ($n=25$)	T2 ($n=25$)	T3 ($n=19$)
Paresthesia				
Any region	10	10	4	4
Face, lips, tongue	8	8	3	3
Hand and fingers	2	2	1	1
Gait disturbance				
Any	21	21	7	7
Objective ataxia on examination	16	16	6	6
Subjective unsteadiness	5	5	1	1
Taste disturbance	7	5	5	5
Dysmetria of the contralateral limb	4	4	1	1
Involuntary movements of the contralateral limb	5	0	5	4
Weakness of the contralateral limb	8	8	5	5
Dysarthria	3	3	1	1
<u>Side effects related to stereotactic frame</u>				
Pin-site bleeding	3			
Numbness of the skull	4			
<u>Side effects related to sonication[#]</u>				
Sensation of "heat", "pressure" or "pain"	14			
"Flipping" sensation	17			
<u>Clinical examination</u>				
SARA Total score[‡]	4.1±3.0	6.5±5.2 ($p=0.072$)	3.9±3.4 ($p=1.000$)	4.2±4.2 ($p=1.000$)
Subitem 1 ("gait")[‡]	1.0±1.4	2.1±1.8 ($p=0.004$)	1.1±1.5 ($p=1.000$)	1.2±1.5 ($p=1.000$)
Subitem 2 ("stance")[‡]	0.6±0.7	1.8±1.4 ($p=0.010$)	0.6±1.0 ($p=1.000$)	0.6±0.8 ($p=1.000$)
MDS-UPDRS IV ("motor complications")[‡]	1.1±2.5	0.5±1.6 ($p=1.000$)	1.4±2.3 ($p=1.000$)	1.9±2.7 ($p=1.000$)

[*]Values are given for 1–3 days (T1), 6 months (T2) and 12 months (T3) after MRgFUS

[#]Side effects related to sonication occurred only during the 10 to 20 s of sonication

[‡]*P* values are based on Friedman test ($p<0.05$) and post hoc analysis using the Wilcoxon signed-rank test and Bonferroni correction for multiple comparisons ($p'<0.017$). Patients with completed 12-months follow-up were included ($n=19$)

MRgFUS Magnetic Resonance-guided Focused Ultrasound, *T1* 1–3 days post-MRgFUS, *T2* 6 months post-MRgFUS, *T3* 12 months post-MRgFUS, *SARA* Scale for the assessment and rating of ataxia

anxiety (STAIT), and the RBDSQ. The mental component scale (MCS) were negatively correlated with the scales BDI, STAIT, AES, and FAQ (Suppl. Table S4).

Safety parameters

Table 4 and Supplementary Table S5 summarize the side effects related to the MRgFUS procedure and during follow-up.

Procedure-related side effects included flipping sensations (68%), sensation of heat, pressure or pain during sonication (56%), transient numbness of the skull (16%), and pin-site bleeding (12%). Side effects related to thalamotomy were gait disturbances (84%), paraesthesias (40%), weakness of the contralateral limb (32%), taste disturbances (28%), reported involuntary movements of the contralateral limb, most likely corresponding to "thalamic" dystonia (20%). dysmetria (16%) or dysarthria (12%). All cases of reported involuntary movements and 2 of the taste disturbances occurred with delay and were reported at the 6 months visit. Gait disturbances could be divided into clear-cut ataxia on examination (76%) and subjective unsteadiness (24%). Paraesthesias mostly involved the face, lips, and tongue (80%), or the fingers of the contralateral hand (20%). The number of side effects and lesion volume at T1 correlated significantly ($r = 0.509$, $p = 0.009$). Furthermore, in patients with more than 2 side effects larger target adjustments were made—mainly in lateral, anterior and inferior direction—but the differences did not reach statistical significance (Suppl. Fig. S1). Further subgroup analyses between patients with and without gait disturbances, paraesthesias or weakness also revealed no significant differences with regard to target adjustments. Lesion volumes at T1 were significantly larger in patients with weakness of the contralateral limb ($Z = -2.15$, $p = 0.03$), however, this was no longer evident after 6 months.

Overall, most side effects were initially classified as mild (62%), 28% as moderate, and 10% as severe. 54% of the side effects were transient, 32% resolved partially within 12 months, and 14% remained unchanged.

The SARA subitems 1 ("gait") and 2 ("stance") showed significantly worsened scores after the treatment (T1), which completely resolved at T2. The MDS-UPDRS IV did not reveal changes in levodopa-related motor complications (Table 4).

Discussion

Our study summarizes motor and non-motor outcomes 12 months after unilateral MRgFUS thalamotomy in patients with medication-refractory tdPD. A tremor improvement of 60% on the CRST$_{mod}$ of the treated side was present 12 months after unilateral MRgFUS thalamotomy, comparable to previous studies, reporting the effects of MRgFUS in PD patients [7–9, 32, 33].

Bradykinesia and rigidity of the treated side improved initially but this effect faded over time—either because of disease progression or more likely edema regression. Previous studies targeting the VLpv nucleus, reported diminishing effects on rigidity, too [32]. The adjacent anterior (VLa) and posterodorsal part (VLpd) of the ventrolateral nucleus (corresponding to the ventri-oralis anterior (Voa) and posterior (Vop) nucleus in the Schaltenbrand atlas[6]), which receive pallidal projections, are considered to be associated with rigidity[34] and thus might be affected by perilesional edema after VLpv ablation.

The average tremor recurrence rate six months after MRgFUS is estimated at around 11% overall, with a worse outcome in PD patients compared to ET [33, 35]. We thus evaluated differences in tremor outcomes with regard to different tremor manifestations and found that 12 months after MRgFUS, patients with concomitant rest and postural tremor showed tremor improvement of 84% on the CRST subscale of the treated side (CRST$_{mod}$), whereas patients with predominant rest tremor had only 38% tremor improvement. Although tremor in PD is typically described as asymmetric rest tremor, accompanying postural tremor is common, including the more frequently observed "re-emergent" tremor and the less common "pure postural tremor" [36]. Although rest and postural tremor in PD may share pathophysiological mechanisms involving interaction of cerebello-thalamocortical and basal ganglia-thalamocortical circuits ("dimmer-switch-hypothesis") [37], different mechanistic hypothesis need to be considered. Transcranial magnetic stimulation in ten PD patients ameliorated rest tremor by stimulation of the primary motor cortex but not by stimulation of the cerebellum, whereas postural tremor was reset by both, suggesting an involvement of the cerebello-thalamocortical tract (CTT) particularly in postural tremor [38]. More precise delineation of lesion localization with regard to different responses of rest and postural tremor might help to decipher the different pathophysiological mechanism.

No significant reduction of the LED or dose of anticholinergics and propranolol was observed after MRgFUS treatment. Previous studies reported prevention of increased LED or delayed need for levodopa on the one hand[8, 39] or unchanged or even increased LED after MRgFUS thalamotomy [9]. Nevertheless, treatment of other symptoms, such as bradykinesia and rigidity in progressive disease, surely contributed to altered medications.

Gait disturbances and paraesthesias were the most common side effects [32, 40]. Consistent with observations in essential tremor patients [17, 41], we also observed taste disturbances and delayed occurrence of involuntary movements, most likely corresponding to "thalamic" dystonia.

Most side effects were mild and improved over time, indicating a consequence of perilesional edema. Recovery in the SARA subitems "gait" and "stance" was evident at the 6-month visit already. Nevertheless, considering that 46% did not fully recover (32% partially recovered), and given the impact of lesion location and target adjustment on the occurrence of side effects, highlights the importance of individualized and precise targeting.

No changes in disability, mood, anxiety, apathy, sleep disturbances or cognition became evident. Previous studies examining the safety of MRgFUS thalamotomy generally used briefer screening batteries to assess changes in disability, mood, or cognition [7–9]. Sperling et al. evaluated non-motor outcomes with an emphasis on cognition in 20 tdPD patients using a comprehensive test battery. They found improvements in QoL and activities of daily living (ADL), but no decline in cognitive function, mood, and behavior 12 months after thalamotomy [10]. Studies on non-motor symptoms following VIM-DBS are also rare, but improvement of ADL, depression, anxiety, and emotional well-being has been reported42. Surprisingly, in our study, tremor severity did not correlate significantly with QoL, while scores measuring disability, mood, anxiety, apathy, sleep, and cognition highly correlated with PDQ-39 and SF-36. Sperling et al. reported similar findings and hypothesized that non-motor symptoms might have a greater impact on QoL than tremor severity [10].

Although we used a comprehensive test battery, most of the tests were based on patient's self-assessment rather than objective clinical testing. Moreover, the MoCA measures global cognitive function and does not refer to specific cognitive domains.

Further limitations of our study are the small sample size as well as the lack of stable medications. As many patients were followed up by their local neurologist in the meantime, there was a lack of meaningful data regarding the reasons for medication adjustments in many cases. While we tried to overcome this disadvantage by conducting the patient's examination in the off-medication state, this was feasible in the outpatient condition only for a 4-h withdrawal, as many patients had to manage a long-distance journey. These limitations may indeed have a considerable impact on the motor outcome as well. Hence, stable dopaminergic therapies are recommended for future investigations.

In conclusion, our results confirm that unilateral MRgFUS thalamotomy in tdPD is reasonably safe and efficient. Using a comprehensive screening test battery, no declines in mood, anxiety, apathy, sleep or cognition were observed. Furthermore, the SARA scores indicated no persistent worsening of gait disturbances after MRgFUS. Interestingly, the motor outcome tended to be better in patients with concomitant postural tremor.

Declarations

References

1. Thenganatt MA, Jankovic J (2014) Parkinson disease subtypes. JAMA Neurol 71:499–504. https://doi.org/10.1001/jamaneurol.2013.6233
2. Bhatia KP, Bain P, Bajaj N et al (2018) Consensus Statement on the classification of tremors. from the task force on tremor of the

International Parkinson and Movement Disorder Society. Mov Disord 33:75–87. https://doi.org/10.1002/mds.27121

3. Wu D-D, Su W, He J et al (2022) Nichtmotorische Symptome und Lebensqualität bei M. Parkinson mit unterschiedlichen motorischen Subtypen (Nonmotor symptoms and quality of life in Parkinson's disease with different motor subtypes). Z Gerontol Geriatr 55:496–501. https://doi.org/10.1007/s00391-021-01950-3

4. Jankovic J, Tan EK (2020) Parkinson's disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 91:795–808. https://doi.org/10.1136/jnnp-2019-322338

5. Schuurman PR, Bosch DA, Bossuyt PM et al (2000) A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N Engl J Med 342:461–468. https://doi.org/10.1056/NEJM200002173420703

6. Schaltenbrand G, Wahren W (1977) Atlas for stereotaxy of the human brain: With an accompanying guide, 2., rev. and enlarged ed. Thieme, Stuttgart

7. Bond AE, Shah BB, Huss DS et al (2017) Safety and efficacy of focused ultrasound thalamotomy for patients with medication-refractory, tremor-dominant parkinson disease: a randomized clinical trial. JAMA Neurol 74:1412–1418. https://doi.org/10.1001/jamaneurol.2017.3098

8. Sinai A, Nassar M, Sprecher E et al (2022) Focused ultrasound thalamotomy in tremor dominant parkinson's disease: long-term results. J Parkinsons Dis 12:199–206. https://doi.org/10.3233/JPD-212810

9. Yamamoto K, Ito H, Fukutake S et al (2021) Focused ultrasound thalamotomy for tremor-dominant Parkinson's disease: a prospective 1-year follow-up study. Neurol Med Chir (Tokyo) 61:414–421. https://doi.org/10.2176/nmc.oa.2020-0370

10. Sperling SA, Shah BB, Barrett MJ et al (2018) Focused ultrasound thalamotomy in Parkinson disease: nonmotor outcomes and quality of life. Neurology 91:e1275–e1284. https://doi.org/10.1212/WNL.0000000000006279

11. Nijhawan SR, Banks SJL, Aziz TZ et al (2009) Changes in cognition and health-related quality of life with unilateral thalamotomy for Parkinsonian tremor. J Clin Neurosci 16:44–50. https://doi.org/10.1016/j.jocn.2008.03.008

12. Lewis SJG, Foltynie T, Blackwell AD et al (2005) Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 76:343–348. https://doi.org/10.1136/jnnp.2003.033530

13. Goetz CG, Tilley BC, Shaftman SR et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23:2129–2170. https://doi.org/10.1002/mds.22340

14. Stacy MA, Elble RJ, Ondo WG et al (2007) Assessment of interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale in essential tremor. Mov Disord 22:833–838. https://doi.org/10.1002/mds.21412

15. Purrer V, Upadhyay N, Borger V et al (2021) Lesions of the cerebello-thalamic tract rather than the ventral intermediate nucleus determine the outcome of focused ultrasound therapy in essential tremor: A 3T and 7T MRI-study. Parkinsonism Relat Disord 91:105–108. https://doi.org/10.1016/j.parkreldis.2021.09.013

16. Chang WS, Jung HH, Kweon EJ et al (2015) Unilateral magnetic resonance guided focused ultrasound thalamotomy for essential tremor: practices and clinicoradiological outcomes. J Neurol Neurosurg Psychiatry 86:257–264. https://doi.org/10.1136/jnnp-2014-307642

17. Purrer V, Borger V, Pohl E et al (2022) Transcranial high-intensity Magnetic Resonance-guided focused ultrasound (tcMRgFUS) - safety and impacts on tremor severity and quality of life. Parkinsonism Relat Disord 100:6–12. https://doi.org/10.1016/j.parkreldis.2022.05.017

18. Elble RJ (2018) Estimating change in tremor amplitude using clinical ratings: recommendations for clinical trials. Tremor Other Hyperkinet Mov (N Y) 8:600. https://doi.org/10.7916/D89C8F3C

19. Schade S, Mollenhauer B, Trenkwalder C (2020) Levodopa equivalent dose conversion factors: an updated proposal including opicapone and safinamide. Mov Disord Clin Pract 7:343–345. https://doi.org/10.1002/mdc3.12921

20. Storch A, Odin P, Trender-Gerhard I et al (2010) Non-motor Symptoms Questionnaire und Scale für das idiopathische Parkinson-Syndrom. Interkulturell adaptierte Versionen in deutscher Sprache (Non-motor Symptoms Questionnaire and Scale for Parkinson's disease. Cross-cultural adaptation into the German language). Nervenarzt 81:980–985. https://doi.org/10.1007/s00115-010-3010-z

21. Bullinger M (1995) German translation and psychometric testing of the SF-36 health survey: preliminary results from the IQOLA project. Soc Sci Med 41:1359–1366. https://doi.org/10.1016/0277-9536(95)00115-N

22. Peto V, Jenkinson C, Fitzpatrick R et al (1995) The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res 4:241–248. https://doi.org/10.1007/BF02260863

23. Beck AT, Steer RA Beck Depressions-Inventar, 2. Aufl. Huber, Bern

24. Yesavage JA, Brink TL, Rose TL et al (1982) Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res 17:37–49. https://doi.org/10.1016/0022-3956(82)90033-4

25. Laux L (1981) Das State-Trait-Angstinventar (STAI): theoretische Grundlagen und Handanweisung. Beltz, Weinheim

26. Lueken U, Seidl U, Schwarz M et al (2006) Die Apathy Evaluation Scale: Erste Ergebnisse zu den psychometrischen Eigenschaften einer deutschsprachigen Ubersetzung der Skala (Psychometric properties of a German version of the Apathy Evaluation Scale). Fortschr Neurol Psychiatr 74:714–722. https://doi.org/10.1055/s-2006-932164

27. Bloch KE, Schoch OD, Zhang JN et al (1999) German version of the Epworth Sleepiness Scale. Respiration 66:440–447. https://doi.org/10.1159/000029408

28. Stiasny-Kolster K, Mayer G, Schäfer S et al (2007) The REM sleep behavior disorder screening questionnaire–a new diagnostic instrument. Mov Disord 22:2386–2393. https://doi.org/10.1002/mds.21740

29. Pfeffer RI, Kurosaki TT, Harrah CH et al (1982) Measurement of functional activities in older adults in the community. J Gerontol 37:323–329. https://doi.org/10.1093/geronj/37.3.323

30. Pillas M, Selai C, Quinn NP et al (2016) Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers). Qual Life Res 25:81–88. https://doi.org/10.1007/s11136-015-1071-y

31. Schmitz-Hübsch T, Du Montcel ST, Baliko L et al (2006) Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66:1717–1720. https://doi.org/10.1212/01.wnl.0000234769.60538.92

32. Chua MMJ, Blitz SE, Ng PR et al. (2023) Focused Ultrasound Thalamotomy for Tremor in Parkinson's Disease: Outcomes in a Large, Prospective Cohort. Mov Disord. https://doi.org/10.1002/mds.29569

33. Zaaroor M, Sinai A, Goldsher D et al (2018) Magnetic resonance-guided focused ultrasound thalamotomy for tremor: a report of 30 Parkinson's disease and essential tremor cases. J Neurosurg 128:202–210. https://doi.org/10.3171/2016.10.JNS16758

34. Narabayashi H, Yokochi F, Nakajima Y (1984) Levodopa-induced dyskinesia and thalamotomy. J Neurol Neurosurg Psychiatry 47:831–839. https://doi.org/10.1136/jnnp.47.8.831

35. Bruno F, Catalucci A, Arrigoni F et al. (2021) Comprehensive Evaluation of Factors Affecting Tremor Relapse after MRgFUS Thalamotomy: A Case-Control Study. Brain Sci 11. https://doi.org/10.3390/brainsci11091183

36. Dirkx MF, Zach H, Bloem BR et al (2018) The nature of postural tremor in Parkinson disease. Neurology 90:e1095–e1103. https://doi.org/10.1212/WNL.0000000000005215

37. Helmich RC, Hallett M, Deuschl G et al (2012) Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits? Brain 135:3206–3226. https://doi.org/10.1093/brain/aws023

38. Ni Z, Pinto AD, Lang AE et al (2010) Involvement of the cerebellothalamocortical pathway in Parkinson disease. Ann Neurol 68:816–824. https://doi.org/10.1002/ana.22221

39. Golfrè Andreasi N, Cilia R, Romito LM et al (2022) Magnetic resonance-guided focused ultrasound thalamotomy may spare dopaminergic therapy in early-stage tremor-dominant Parkinson's disease: a pilot study. Mov Disord 37:2289–2295. https://doi.org/10.1002/mds.29200

40. Segar DJ, Lak AM, Lee S et al (2021) Lesion location and lesion creation affect outcomes after focused ultrasound thalamotomy. Brain 144:3089–3100. https://doi.org/10.1093/brain/awab176

41. Purrer V, Upadhyay N, Borger V et al (2023) Structural and functional alterations in the gustatory network underlie taste disturbances after lesional tremor therapy with MRgFUS. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2023-331324

42. Woods SP, Fields JA, Lyons KE et al. (2001) Neuropsychological and quality of life changes following unilateral thalamic deep brain stimulation in Parkinson's disease: a one-year follow-up. Acta Neurochir (Wien) 143:1273–7; discussion 1278. https://doi.org/10.1007/s007010100024